CD45RA<sup>+</sup>CCR7<sup>-</sup> CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab.

J Immunother Cancer · 2019 · PMC6555948 · PMID 31176366

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Moreover, PR but not PD patients showed a trend of increased frequency of CD45RA + CCR7 − CD8 T cells during nivolumab treatment (52 and 31% at V1 for PR and PD, respectively).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.